<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00708656</url>
  </required_header>
  <id_info>
    <org_study_id>HAW0105</org_study_id>
    <secondary_id>ISRCTN:35600632</secondary_id>
    <secondary_id>EudraCT Number:2005-002784-91</secondary_id>
    <nct_id>NCT00708656</nct_id>
  </id_info>
  <brief_title>The Colitis Once Daily Asacol Study</brief_title>
  <acronym>CODA</acronym>
  <official_title>A Randomized, Single-Blind Study to Assess Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily Versus Divided Doses 3 Times Daily for 12 Months in Maintenance of Remission of Ulcerative Colitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiff and Vale University Health Board</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Procter and Gamble</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardiff and Vale University Health Board</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of dosing mesalazine 800&#xD;
      mg tablets (Asacol®) at 2.4 g once daily versus divided doses three times daily in the&#xD;
      maintenance of remission of ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design&#xD;
&#xD;
        -  Multicentre, randomized, single-blind, comparator-controlled, parallel-armed study&#xD;
&#xD;
        -  One year follow-up, or until relapse (whichever shorter)&#xD;
&#xD;
        -  40-60 UK centres&#xD;
&#xD;
      Subject population&#xD;
&#xD;
        -  Ulcerative colitis in remission (sigmoidoscopy score of 0 or 1 with no symptoms of&#xD;
           active disease, with no treatment for active colitis) for at least 4 weeks, and for no&#xD;
           more than 2 years&#xD;
&#xD;
        -  Taking mesalazine or sulfasalazine prior to study entry&#xD;
&#xD;
        -  Patients excluded if they have Crohn's disease, symptoms of active colitis, have used&#xD;
           corticosteroids, ciclosporin or oral/enema mesalazine in the past 4 weeks, are&#xD;
           intolerant to mesalazine or Asacol, are pregnant or lactating, or have known HIV,&#xD;
           hepatic disease, renal impairment or other serious medical or psychiatric illness&#xD;
&#xD;
        -  Sample size 250&#xD;
&#xD;
        -  Gender: male or female&#xD;
&#xD;
        -  Ethnicity: no restriction&#xD;
&#xD;
        -  Age: over 18&#xD;
&#xD;
      Test Product&#xD;
&#xD;
      Once daily group: Asacol® 2.4g daily given as three 800mg tablets orally qAM&#xD;
&#xD;
      Three times daily group: Asacol® 2.4g daily given as one 800mg tablet orally three times&#xD;
      daily&#xD;
&#xD;
      Criteria for Evaluation:&#xD;
&#xD;
      Primary Outcome Variable: Relapse rate over 1 year in the intention to treat population, with&#xD;
      the study powered to detect non-inferiority of the once-daily regimen.&#xD;
&#xD;
      Secondary Outcome Variables: assessment of superiority of the once-daily regimen, if&#xD;
      non-inferiority is demonstrated; safety analysis; per protocol analysis of relapse rate; time&#xD;
      course of relapse; medication compliance; changes in modified Baron sigmoidoscopy scores&#xD;
      between trial entry and relapse/12 month; impact of various factors on relapse rate (time&#xD;
      from last relapse at study entry, concomitant azathioprine or 6-mercaptopurine therapy;&#xD;
      disease extent; disease duration; smoking status; age at diagnosis; previous dose of&#xD;
      mesalazine; baseline calprotectin; baseline CRP level).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess whether a once daily dose of three 800mg tablets of mesalazine (Asacol®) in the morning is equivalent to mesalazine (Asacol®) given as 800mg three times daily in preventing relapse over a 12 month period.</measure>
    <time_frame>At relapse or 12 month follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess equivalence in terms of safety</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess equivalence in terms of time to relapse</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess equivalence in terms of progression of disease (measured by Mayo score)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>1: once daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three 800mg tablets of mesalazine (Asacol®) in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2: tds</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mesalazine (Asacol®) 800mg given three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mesalazine (Asacol®)</intervention_name>
    <description>800 mg tablets</description>
    <arm_group_label>1: once daily</arm_group_label>
    <arm_group_label>2: tds</arm_group_label>
    <other_name>Mesalazine</other_name>
    <other_name>Asacol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who meet the following criteria will be eligible for study entry:&#xD;
&#xD;
          -  Male and female patients aged over 18 with ulcerative colitis confirmed by histology&#xD;
             who are in remission (no symptoms of active disease, and modified Baron sigmoidoscopic&#xD;
             score of 0 or 1)&#xD;
&#xD;
          -  If female, must be (as documented in patient notes):&#xD;
&#xD;
               -  postmenopausal (at least 1 year without spontaneous menses), or&#xD;
&#xD;
               -  surgically sterile (tubal ligation or hysterectomy at least 6 months prior to&#xD;
                  enrollment), or&#xD;
&#xD;
               -  using acceptable contraception (e.g., oral, intramuscular, or implanted hormonal&#xD;
                  contraception) at least 3 months prior to enrollment, or&#xD;
&#xD;
               -  have a sexual partner with non-reversed vasectomy (with confirmed azoospermia),&#xD;
                  or&#xD;
&#xD;
               -  be using 1 barrier method (e.g., condom, diaphragm, spermicide, or intra-uterine&#xD;
                  device)&#xD;
&#xD;
          -  Patients whose ulcerative colitis has been in clinical remission for 4 weeks or&#xD;
             longer, and who have had a symptomatic relapse within the past two years&#xD;
&#xD;
          -  Patients taking mesalazine, sulfasalazine or other drug containing 5-ASA for 4 weeks&#xD;
             or longer&#xD;
&#xD;
          -  Patients capable of giving written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The following patients will be excluded from the study:&#xD;
&#xD;
          -  Patients with Crohn's disease&#xD;
&#xD;
          -  Patients with symptoms of active colitis&#xD;
&#xD;
          -  Modified Baron sigmoidoscopy score of 2 or 3&#xD;
&#xD;
          -  Patients who have used oral, enema, intravenous or suppository preparations of&#xD;
             corticosteroids, oral or intravenous ciclosporin, mesalazine enemas or suppositories&#xD;
             within the past four weeks&#xD;
&#xD;
          -  Patients taking azathioprine or 6-mercaptopurine who have altered the dose or started&#xD;
             treatment within the past three months, (these drugs permitted in stable dose during&#xD;
             the study)&#xD;
&#xD;
          -  Patients with intolerance to Asacol 400 mg or mesalazine&#xD;
&#xD;
          -  Women who are pregnant or lactating&#xD;
&#xD;
          -  Patients with known HIV infection&#xD;
&#xD;
          -  Patients with hepatic disease&#xD;
&#xD;
          -  Patients with renal impairment (creatinine above local reference range), or with&#xD;
             positive urine dipstick test to blood or protein&#xD;
&#xD;
          -  Other serious medical or psychiatric illness that in the opinion of the investigator&#xD;
             would possibly comprise the study&#xD;
&#xD;
          -  Patients with problem alcohol excess or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr A B Hawthorne</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiff and Vale University Health Board</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor C Probert</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bristol Royal Infirmary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnsley District General Hospital</name>
      <address>
        <city>Barnsley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Hampshire Hospital</name>
      <address>
        <city>Basingstoke</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Selly Oak Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bishop Auckland General Hospital</name>
      <address>
        <city>Bishop Auckland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blackpool Victoria Hospital</name>
      <address>
        <city>Blackpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glan Clwyd Hospital</name>
      <address>
        <city>Bodelwyddan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pilgrim Hospital</name>
      <address>
        <city>Boston</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Royal Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Llandough Hospital</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Infirmary</name>
      <address>
        <city>Carlisle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walsgrave Hospital</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derby City General Hospital</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr M Al-Najjar</name>
      <address>
        <city>Doncaster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russells Hall Hospital</name>
      <address>
        <city>Dudley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Durham</name>
      <address>
        <city>Durham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stobhill Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gloucester Royal Hospital</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Hartlepool</name>
      <address>
        <city>Hartlepool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Glamorgan Hospital</name>
      <address>
        <city>Llantrisant</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital</name>
      <address>
        <city>Louth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luton &amp; Dunstable Hospital</name>
      <address>
        <city>Luton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Macclesfield District General Hospital</name>
      <address>
        <city>Macclesfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borders General Hospital</name>
      <address>
        <city>Melrose</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Merthyr Tydfil</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Norwich</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poole General Hospital</name>
      <address>
        <city>Poole</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Berkshire Hospital</name>
      <address>
        <city>Reading</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotherham District General Hospital</name>
      <address>
        <city>Rotherham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Tees &amp; University Hospital of Hartlepool</name>
      <address>
        <city>Stockton on Tees</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Cornwall Hospital</name>
      <address>
        <city>Truro</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Hospital</name>
      <address>
        <city>Welwyn Garden City</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra Hospital</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worcester Royal Infirmary</name>
      <address>
        <city>Worcester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Worthing</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York District Hospital</name>
      <address>
        <city>York</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>April 8, 2008</study_first_submitted>
  <study_first_submitted_qc>July 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2008</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IBD</keyword>
  <keyword>Colitis</keyword>
  <keyword>UC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesalamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

